Magdalena J Å**å**usarz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6898617/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Investigation of the Effects of Primary Structure Modifications within the RRE Motif on the Conformation of Synthetic Bovine Herpesvirus 1â€Encoded UL49.5 Protein Fragments. Chemistry and Biodiversity, 2021, 18, e2000883. | 2.1 | 1 |
| 2 | PTD4 Peptide Increases Neural Viability in an In Vitro Model of Acute Ischemic Stroke. International Journal of Molecular Sciences, 2021, 22, 6086. | 4.1 | 5 |
| 3 | Modeling protein structures with the coarse-grained UNRES force field in the CASP14 experiment. Journal of Molecular Graphics and Modelling, 2021, 108, 108008. | 2.4 | 17 |
| 4 | Structure determination of UL49.5 transmembrane protein from bovine herpesvirus 1 by NMR spectroscopy and molecular dynamics. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 926-938. | 2.6 | 8 |
| 5 | Vasopressin V1a and V1b receptor modulators: a patent review (2012 – 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 711-722. | 5.0 | 6 |
| 6 | Exploring the Ligand Recognition Properties of the Human Vasopressin <scp>V</scp> 1a Receptor Using <scp>QSAR</scp> and Molecular Modeling Studies. Chemical Biology and Drug Design, 2014, 83, 207-223. | 3.2 | 10 |
| 7 | Theoretical studies, synthesis, and biological activity of 1-[(4-methylphenyl)sulfonyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carbonitrile (C9) as a non-peptide antagonist of the arginine vasopressin V1a and V2 receptors. Medicinal Chemistry Research, 2014, 23, 1581-1590. | 2.4 | 4 |
| 8 | Interactions of vasopressin and oxytocin receptors with vasopressin analogues substituted in position 2 with 3,3′â€diphenylalanine – a molecular docking study. Journal of Peptide Science, 2013, 19, 118-126. | 1.4 | 6 |
| 9 | Molecular modeling study of the opioid receptor interactions with series of cyclic deltorphin analogues. Journal of Peptide Science, 2011, 17, 554-564. | 1.4 | 0 |
| 10 | Conformational stability of the fullâ€ e tom hexameric model of the ClpB chaperone from <i>Escherichia coli</i> . Biopolymers, 2010, 93, 47-60. | 2.4 | 14 |
| 11 | Influence of bulky 3,3′-diphenylalanine enantiomers replacing position 2 of AVP analogues on their conformations: NMR and molecular modeling studies. European Journal of Medicinal Chemistry, 2010, 45, 4065-4073. | 5.5 | 8 |
| 12 | Oxytocin-Gly-Lys-Arg: A Novel Cardiomyogenic Peptide. PLoS ONE, 2010, 5, e13643. | 2.5 | 23 |
| 13 | Molecular Dynamics Study of the Internal Water Molecules in Vasopressin and Oxytocin Receptors. Protein and Peptide Letters, 2009, 16, 342-350. | 0.9 | 4 |
| 14 | Molecular Docking-Based Study of Vasopressin Analogues Modified at Positions 2 and 3 withN-Methylphenylalanine:A Influence on Receptor-Bound Conformations and Interactions with Vasopressin and Oxytocin Receptors. Journal of Medicinal Chemistry, 2006, 49, 2463-2469. | 6.4 | 31 |
| 15 | Investigation ofcis/trans ratios of peptide bonds in AVP analogues containingN-methylphenylalanine enantiomers. Journal of Peptide Science, 2006, 12, 13-24. | 1.4 | 7 |
| 16 | Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin—modeling of an activated state. Journal of Peptide Science, 2006, 12, 171-179. | 1.4 | 27 |
| 17 | Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors—molecular dynamics study of the activated receptor–vasopressin–Gα systems. Journal of Peptide Science, 2006, 12, 180-189. | 1.4 | 33 |
| 18 | Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: Molecular dynamics simulation of the agonist-bound state in the membrane–aqueous system. Biopolymers, 2006, 81, 321-338. | 2.4 | 24 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Conformational studies of vasopressin analogues modified with N-methylphenylalanine enantiomers in dimethyl sulfoxide solution. Biopolymers, 2006, 82, 603-614. | 2.4 | 10 |
| 20 | Molecular Modeling of the Neurohypophyseal Receptor/Atosiban Complexes. Protein and Peptide Letters, 2003, 10, 295-302. | 0.9 | 15 |